You are here: Industry Insights > Tumor

News List

The Classification of Sesquiterpene Compounds and Their Research Progress Xiaomichong
May 23, 2024
Terpenoids are an important part of natural organic compounds, and there are currently more than 50,000 reported terpenoid structures.
Competitive Landscape of the New Drug Target Nectin-4 in China Yefenghong/PharmaSources
May 22, 2023
Araris Biotech AG announced on April 17 that it will acquire ARS Pharmaceutical's Nectin-4 antibody. Araris Biotech intends to use the acquired Nectin-4 antibody to develop differentiated Nectin-4 ADCs using its proprietary linker technology.
A New Target in ADC: Nectin-4 PharmaSources/Yefenghong
September 14, 2021
Recently, the application for clinical trail of Mabwell's ADC drug (9MW2821) targeting Nectin-4 has been accepted by NMPA. It is the first time that domestic enterprise enters the IND stage with the same target drug.
Drug Research and Development of Targeting STAT3: Next Outlet for Antitumor Drugs PharmaSources/Yuntian
August 11, 2021
STAT3 is a major member of signal transduction and activating transcription factor (STAT). According to some studies, it is verified that STAT3 can regulate the growth cycle and immune response of cells.
A Glimpse of the Oncology Drug Treatment Market in China PharmaSources/Xiaoyaowan
May 31, 2021
According to statistics, the market size of China’s oncology treatment industry reached RMB387.6 billion in 2020, with a compound annual growth rate of 10.3% in the past five years as compared to RMB261.4 billion in 2016, and this market size is expected
With Zero Five-Year Recurrences, the Emerging Tumor Vaccine Brings Hope of Cure PharmaSources/Wang Hong
January 21, 2021
Undoubtedly, vaccines are one of the most significant milestone inventions in mankind’s fight against diseases, and they have also played an essential role in the treatment of cancer.
The tumor disappears after infection with coronavirus! Looking at the “killing cancer with the virus” concept in the oncology field PharmaSources/Wang Hong
January 21, 2021
The world is full of wonders. According to an article published by a British doctor in the British Journal of Haematology two days ago, a malignant lymphoma patient’s tumor almost disappeared after infection with coronavirus!
Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting PharmaSources
April 18, 2023
April 18, 2023，Data of InnoCare’s robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China PharmaSources
March 10, 2023
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 inhibitor ICP-248 in China.
Immune-Based Therapy Shows Promise Against Advanced Breast Cancers drugs.com
February 09, 2022
An experimental therapy that harnesses the body's tumor-fighting immune cells...

Previous page 1 2 3 4 5 6 7 Next page